Hepatocyte Growth Factor Induces Gefitinib Resistance of Lung Adenocarcinoma with Epidermal Growth Factor Receptor–Activating Mutations

Seiji Yano,1 Wei Wang,1 Qi Li,1 Kunio Matsumoto,2 Haruko Sakurama,2 Takahiro Nakamura,2 Hirokazu Ogino,3 Soji Kakiuchi,3 Masaki Hanibuchi,1 Yasuhiko Nishioka,3 Hisanori Uehara,4 Tetsuya Mitsudomi,1 Yasushi Yatabe,1 Toshikazu Nakamura,1 and Saburo Sone3

Divisions of 1Medical Oncology and 2Tumor Dynamics and Regulation, Cancer Research Institute, Kanazawa University, Kanazawa, Ishikawa, Japan; Departments of 3Respiratory Medicine and Rheumatology and 4Molecular and Environmental Pathology, University of Tokushima Graduate School, Tokushima, Tokushima, Japan; Departments of 5Thoracic Surgery and 6Pathology, Aichi Cancer Center Hospital, Nagoya, Aichi, Japan; and 7Division of Molecular Regenerative Medicine, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.

Abstract

Lung cancer with epidermal growth factor receptor (EGFR)–activating mutations responds favorably to the EGFR tyrosine kinase inhibitors gefitinib and erlotinib. However, 25% to 30% of patients with EGFR-activating mutations show intrinsic resistance, and the responders invariably acquire resistance to gefitinib. Here, we showed that hepatocyte growth factor (HGF), a ligand of MET oncoprotein, induces gefitinib resistance of lung adenocarcinoma cells with EGFR-activating mutations by restoring the phosphatidylinositol 3-kinase/Akt signaling pathway via phosphorylation of MET, but not EGFR or ErbB3. Strong immunoreactivity for HGF in cancer cells was detected in lung adenocarcinoma patients harboring EGFR-activating mutations, but no T790M mutation or MET amplification, who showed intrinsic or acquired resistance to gefitinib. The findings indicate that HGF-mediated MET activation is a novel mechanism of gefitinib resistance in lung adenocarcinoma with EGFR-activating mutations. Therefore, inhibition of HGF-MET signaling may be a considerable strategy for more successful treatment with gefitinib. [Cancer Res 2008;68(22):9479–87]

Introduction

Lung cancer is one of the most prevalent malignancies and the leading cause of cancer-related death worldwide. Non–small-cell lung cancer (NSCLC) accounts for nearly 80% of lung cancer cases. The median survival of metastatic NSCLC is 8 to 10 months when treated with the most active combination of conventional chemotherapeutic agents (1, 2). Recent therapeutic strategies for NSCLC have focused on the development of molecular targeted therapies.

Epidermal growth factor receptor (EGFR) is a member of a family of closely related growth factor receptor tyrosine kinases, which includes EGFR (ErbB1), HER2/neu (ErbB2), HER3 (ErbB3), and HER4 (ErbB4; ref. 3). As EGFR is expressed in the majority of cases of NSCLC, it is an attractive target for the development of therapeutic agents. The small-molecule EGFR tyrosine kinase inhibitors, including gefitinib and erlotinib, have been evaluated in clinical trials for patients with NSCLC. Both agents cause partial responses in 10% to 20% of all NSCLC patients (4, 5).

Activating mutations in EGFR have been found in a proportion of NSCLC (6, 7). Almost 90% of the activating mutations in EGFR consist of in-frame deletions in exon 19 and L858R point mutation in exon 21. These mutations are predominantly found in female, nonsmoking, adenocarcinoma patients and in patients of East Asian origin, and are associated with favorable response to the EGFR tyrosine kinase inhibitors, gefitinib and erlotinib (8). Multiple prospective trials have shown a response rate of 70% to 75% for patients with tumors harboring these mutations (8, 9). This indicates, however, that another 25% to 30% of the patients are intrinsically resistant to EGFR tyrosine kinase inhibitors although their tumors harbor activating mutations in EGFR. In addition, even patients who show a dramatic response to initial treatment also develop acquired resistance to the EGFR tyrosine kinase inhibitors almost without exception after varying periods of time (8).

To overcome the intrinsic and acquired resistance to EGFR tyrosine kinase inhibitors, it is necessary to clarify the molecular mechanisms of the resistance. Recently, two mechanisms, second-site mutation that substitutes methionine for threonine at position 790 (T790M) in EGFR (10, 11) and amplification of MET proto-oncogene (12, 13), which contribute to acquired resistance to EGFR tyrosine kinase inhibitors, have been reported. T790 is located in the ATP-binding pocket of the catalytic region of EGFR and seems to be critical for the binding of erlotinib and gefitinib (10). On acquisition of a secondary T790M mutation, the bulkier methionine residue prevents EGFR tyrosine kinase inhibitor from binding with EGFR tyrosine kinases. On the other hand, MET amplification has been shown to restore the phosphatidylinositol 3-kinase (PI3K)/Akt pathway mediated by ErbB3 transactivation and thereby induces acquired resistance to gefitinib. T790M secondary mutation and MET amplification are found in ~50% and 20%, respectively, of patients acquiring resistance to EGFR tyrosine kinase inhibitors (8, 10–13). However, the mechanisms of intrinsic resistance and the other 30% of cases of acquired resistance are still unknown.

The MET gene encodes a high-affinity receptor for hepatocyte growth factor (HGF; refs. 14, 15). HGF, originally cloned as a mitogenic protein for hepatocytes (16), specifically activates MET receptor tyrosine kinase and induces pleiotropic biological effects...
in a wide variety of cells, including mitogenic, motogenic, morphogenic, and antiapoptotic activities (17, 18). As HGF is expressed in lung cancer cells and stromal cells (17–19), we investigated whether HGF is involved in gefitinib resistance of lung adenocarcinoma cells with EGFR-activating mutations. In contrast with MET amplification, we found that HGF induces resistance to gefitinib by restoring Akt phosphorylation independently of ErbB3 and that HGF can be involved in intrinsic resistance as well as acquired resistance to gefitinib in lung adenocarcinoma patients with EGFR-activating mutations.

Materials and Methods

Cell culture and reagents. The EGFR-mutant human lung adenocarcinoma cell lines PC-9 and HCC827 were purchased from Immuno-Biological Laboratories Co. and American Type Culture Collection, respectively. These cell lines were extensively characterized (12, 20, 21). Human lung squamous cell carcinoma, EBC-1 (22), was purchased from the Health Science Research Resources Bank (Japan Health Sciences Foundation). PC-9, HCC827, and EBC-1 cell lines were maintained in RPMI 1640 supplemented with 10% fetal bovine serum (FBS), 100 units/mL penicillin, 100 units/mL streptomycin, and 2 mmol/L glutamine.

Gefitinib was obtained from AstraZeneca. Recombinant HGF and anti-HGF antibody for immunohistochemistry were prepared as reported previously (23, 24). Recombinant epidermal growth factor (EGF) and insulin-like growth factor I (IGF-I) were obtained from Invitrogen. Transforming growth factor α (TGF-α) was from Biosource. Goat antihuman HGF neutralizing antibody and control goat IgG were purchased from R&D Systems.

Sequence analyses. We searched for mutations in the EGFR gene in lung adenocarcinoma cell lines by sequencing the cDNAs synthesized from biological samples.

Figure 1. HGF induces gefitinib resistance of lung adenocarcinoma cells with EGFR-activating mutations. A, HGF induced gefitinib resistance of PC-9 and HCC827 cells with EGFR-activating mutation. Tumor cells were incubated with increasing concentrations of gefitinib and/or HGF, and cell growth was determined after 72 h of treatment by MTT assay. B, pretreatment of HGF with anti-HGF antibody abrogated HGF-induced resistance of HCC827 cells to gefitinib. HGF (20 ng/mL) was pretreated with control IgG (2 μg/mL) or anti-HGF antibody (2 μg/mL) at 37°C for 1 h. The resultant solutions were added to the cultures of tumor cells with or without gefitinib (300 nmol/L). Cell growth was determined in the same way as in A. *, P < 0.01 (one-way ANOVA). C, HGF was most potent in induction of gefitinib resistance of PC-9 and HCC827 cells. PC-9 and HCC827 cells were incubated with or without gefitinib and/or 50 ng/mL of HGF, EGF, TGF-α, or IGF-I. Cell growth was determined after 72 h of treatment. The percentage of growth is shown relative to untreated controls.
Cell proliferation assay. Cell proliferation was measured using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium (MTT) dye reduction method (25). Tumor cells (2 × 10^5/100 μL/well) were plated into each well of 96-well plates in RPMI 1640 with 10% FBS. After 24 h incubation, several concentrations of gefitinib, cytokines, and/or culture supernatants were added to each well, and incubation was continued for a further 72 h. Then, 50 μL of MTT solution (2 mg/mL; Sigma) were added to all wells, and incubation was continued for a further 2 h. The media containing MTT solution were removed, and the dark blue crystals were dissolved by adding 250 μL of DMSO. The absorbance was measured with a microplate reader at test and reference wavelengths of 550 and 630 nm, respectively. The percentage of growth is shown relative to untreated controls. Each experiment was done at least in triplicate, and thrice independently.

Cell apoptosis assay. Cell apoptosis induced by gefitinib was detected with an Annexin V-FITC Apoptosis Detection Kit I (BD Biosciences) in accordance with the manufacturer’s protocols. Briefly, aliquots of 5 × 10^5 cells were stained with Annexin V-FITC and PI according to the kit instructions. The stained cells were analyzed by flow cytometry and subpopulations of early apoptosis (Annexin V-positive, PI-negative), late apoptosis (Annexin V-positive, PI-positive), and necrosis (Annexin V-negative, PI-positive) were determined. Percentage of early apoptosis is shown relative to untreated controls. Each experiment was done in triplicate, and thrice independently.

Quantitative PCR for analysis of MET genomic amplification. Quantitative PCR was done on genomic DNA purified with a QIAamp DNA Mini kit (Qiagen). Primers and probe were designed for MET were (5’ to 3’): F-TGTTGCAAGCTTGTACCCATC, R-TCTCTGTTAGGCATGCTGTCTC, and FAM-TGGATAATTGTGTCTTTCTCTAG-MGBNFQ (22). Primers and probe for the single-copy reference gene Rnase P, which encodes the RNA moiety of the enzyme RNase P, were obtained from Applied Biosystems, as well as TaqMan Gene Expression Master Mix. Reactions were done in 96-well plates with 20 ng of genomic DNA, primers at 900 nmol/L, and probes at 250 nmol/L under standard thermocycling conditions (2 min at 50°C; 10 min at 95°C; 40 cycles of 15 s at 92°C and 1 min at 60°C). Data were normalized to Rnase P.

HGF Induces Gefitinib Resistance

Figure 2. HGF induces gefitinib resistance of lung adenocarcinoma cells with EGFR-activating mutations by restoring phosphorylation of Akt, but not EGFR or ErbB3. A, the phosphorylation of Akt, but not EGFR or ErbB3, was restored by HGF. Tumor cells were treated with or without gefitinib (300 nmol/L) and/or HGF (20 ng/mL) for 1 h. Cells were lysed, and the indicated proteins were detected by immunoblotting. B, cell extracts were immunoprecipitated with an antibody to MET or p85. The precipitated proteins were determined by immunoblotting with the indicated antibodies.

<table>
<thead>
<tr>
<th></th>
<th>PC-9</th>
<th>HCC827</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gefitinib</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>HGF</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>p-EGFR 1086</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>p-EGFR 1088</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>EGFR</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>p-ErbB3</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>ErbB3</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>p-MET</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>MET</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>p-akt</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Akt</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>p-Erk1/2</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Erk1/2</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

(Bio-Rad). After washing four times, membranes were incubated with Blocking One (Nacalai Tesque, Inc.) for 1 h at room temperature and then incubated overnight at 4°C with the following primary antibodies: anti-Met (Z5H2), anti–phospho-Met (Y1234/Y1235) (3D7), anti–phospho EGFR (Y1068), anti-ErbB3 (B2), anti–phospho-ErbB3 (Tyr1238) (B2D3), PI3K p85 (19H8), phospho-PI3K p85Y298/307 (1H9), anti-Akt, or phospho-Akt (Ser473) antibodies (1:1,000 dilution, Cell Signaling Technology), and anti-human EGFR (1 μg/mL), anti-human/mouse/nrat extracellular signal-regulated kinase (ERK)-1/2 (0.2 μg/mL), or anti–phospho ERK1/2 (T202/Y204) (0.1 μg/mL) antibodies (R&D Systems). After washing thrice, membranes were incubated for 1 h at room temperature with species-specific horseradish peroxidase–conjugated secondary antibodies. Immunoreactive bands were visualized with SuperSignal West Dura Extended Duration Substrate Enhanced Chemiluminescent Substrate (Pierce Biotechnology). Each experiment was done at least thrice independently.
Assay for RNA interference and HGF gene transfection. Duplexed Stealth RNAi (Invitrogen) against MET and ErbB3 and Stealth RNAi Negative Control Low GC Duplex #3 (Invitrogen) were used for RNA interference (RNAi) assay. The full-length HGF cDNA cloned into an expression vector (26) was used for HGF gene transfection assay. One day before transfection, aliquots of 2 x 10^4 tumor cells in 400 μL of antibiotic-free medium were plated on 24-well plates. After incubation for 24 h, the cells were transfected with small interfering RNA (siRNA; 50 pmol) or scramble RNA using Lipofectamine 2000 (1 μL) in accordance with the manufacturer's instructions. After 24-h incubation, the cells were washed with PBS and incubated with or without gefitinib (300 nmol/L) and/or recombinant human HGF (20 ng/mL) for an additional 72 h in antibiotic-containing medium. Cell proliferation was measured with a Cell Counting Kit-8 (Dojin) in accordance with the manufacturer's instructions. Knockdown of MET and ErbB3 was confirmed by reverse transcription-PCR (RT-PCR) analysis. The sequences of siRNAs were as follows: MET, 5'-UCCAGAAGACGUUCCUUAAUCA-3' and 5'-UGAAUUAGGAUCUUGGA-5'; ErbB3, 5'-GGCCAUUGAAUUCUCAUCUA-3' and 5'-UAGAGUAGGAAUCAUCUGCC-3'. Each experiment was done at least in triplicate, and thrice independently.

HGF production. Cells (1 x 10^4) were cultured in RPMI 1640 with 10% FBS for 24 h. The cells were washed with PBS and incubated for 48 h in RPMI 1640 with 10% FBS. Then, culture medium was harvested and centrifuged, and the supernatant was stored at −70°C until analysis. For determination of HGF, ELISA was done in accordance with the manufacturer's recommended procedures (Immunis HGF EIA, Institute of Immunology, Tokyo, Japan). All samples were run in triplicate. Color intensity was measured at 450 nm with a spectrophotometric plate reader. Growth factor concentrations were determined by comparison with standard curves. The detection limit was 0.1 ng/mL.

Patients. In total, 20 tumor specimens with EGFR-activating mutations were obtained from 16 lung adenocarcinoma patients, who provided written informed consent, at the Tokushima University Hospital (Tokushima, Japan) and Aichi Cancer Center Hospital (Nagoya, Japan) in Institutional Review Board–approved studies. Of the 16 patients, 3 patients showed intrinsic resistance and other 13 patients showed partial response.
Table 1. Summary of tissue samples from patients with lung adenocarcinoma with EGFR-activating mutations

<table>
<thead>
<tr>
<th>Patient</th>
<th>Specimen Type</th>
<th>BOR</th>
<th>EGFR mutation</th>
<th>T790M</th>
<th>MET amplification</th>
<th>HGF</th>
<th>MET</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Pretreatment specimens</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>Pre-gefitinib Primary lung cancer</td>
<td>PD</td>
<td>L858R</td>
<td>N</td>
<td>N</td>
<td>High</td>
<td>2+</td>
</tr>
<tr>
<td>2</td>
<td>Pre-gefitinib Primary lung cancer</td>
<td>SD</td>
<td>L858R</td>
<td>N</td>
<td>N</td>
<td>High</td>
<td>3+</td>
</tr>
<tr>
<td>3</td>
<td>Pre-gefitinib Lymph node</td>
<td>PD</td>
<td>L858R</td>
<td>N</td>
<td>N</td>
<td>High</td>
<td>3+</td>
</tr>
<tr>
<td></td>
<td>Paired specimens</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>Pre-gefitinib Primary lung cancer</td>
<td>PR</td>
<td>Ex19Del</td>
<td>N</td>
<td></td>
<td>Low</td>
<td>3+</td>
</tr>
<tr>
<td>5</td>
<td>Pre-gefitinib Primary lung cancer</td>
<td>PR</td>
<td>Ex19Del</td>
<td>Y</td>
<td>N</td>
<td>Low</td>
<td>1+</td>
</tr>
<tr>
<td>6</td>
<td>Pre-gefitinib Primary lung cancer</td>
<td>PR</td>
<td>Ex19Del</td>
<td>Y</td>
<td>N</td>
<td>Low</td>
<td>3+</td>
</tr>
<tr>
<td>7</td>
<td>Post-gefitinib Lymph node</td>
<td>PR</td>
<td>L858R</td>
<td>N</td>
<td>N</td>
<td>High</td>
<td>3+</td>
</tr>
<tr>
<td>8</td>
<td>Post-gefitinib Lung metastasis</td>
<td>PR</td>
<td>L858R</td>
<td>N</td>
<td>N</td>
<td>Low</td>
<td>2+</td>
</tr>
<tr>
<td>9</td>
<td>Post-gefitinib Lung metastasis</td>
<td>PR</td>
<td>L858R</td>
<td>N</td>
<td>N</td>
<td>Low</td>
<td>2+</td>
</tr>
<tr>
<td>10</td>
<td>Post-gefitinib Lung metastasis</td>
<td>PR</td>
<td>L858R</td>
<td>Y</td>
<td>N</td>
<td>Low</td>
<td>2+</td>
</tr>
<tr>
<td>11</td>
<td>Post-gefitinib Lung metastasis</td>
<td>PR</td>
<td>L858R</td>
<td>Y</td>
<td>N</td>
<td>Low</td>
<td>3+</td>
</tr>
<tr>
<td>12</td>
<td>Post-gefitinib Lung metastasis</td>
<td>PR</td>
<td>L858R</td>
<td>Y</td>
<td>N</td>
<td>Low</td>
<td>3+</td>
</tr>
<tr>
<td>13</td>
<td>Post-gefitinib Lung metastasis</td>
<td>PR</td>
<td>L858R</td>
<td>Y</td>
<td>N</td>
<td>Low</td>
<td>3+</td>
</tr>
<tr>
<td>14</td>
<td>Post-gefitinib Primary lung cancer</td>
<td>PR</td>
<td>L858R</td>
<td>N</td>
<td>N</td>
<td>Low</td>
<td>3+</td>
</tr>
<tr>
<td>15</td>
<td>Post-gefitinib Primary lung cancer</td>
<td>PR</td>
<td>L858R</td>
<td>N</td>
<td>N</td>
<td>Low</td>
<td>3+</td>
</tr>
<tr>
<td>16</td>
<td>Post-gefitinib Lymph node</td>
<td>PR</td>
<td>Ex19Del</td>
<td>N</td>
<td>N</td>
<td>High</td>
<td>3+</td>
</tr>
</tbody>
</table>

**Abbreviations:** BOR, best overall response to gefitinib treatment; PR, partial response; SD, stable disease; PD, progressive disease; L858R, L858R point mutation in exon 21; Ex19Del, in-frame deletion in exon 19; N, no; Y, yes; NE, not evaluated.

to initial gefitinib treatment. For the 3 patients who showed intrinsic resistance and 8 of the 13 patients who had shown partial response, tumor specimens were obtained only before gefitinib treatment. The other 5 had shown partial response to gefitinib during initial treatment but showed signs of tumor regrowth (i.e., acquired resistance) while still receiving gefitinib. For 3 of those 5 patients, we were able to obtain pairs of tumor specimens before treatment and after the development of acquired resistance to gefitinib. In the other 2 patients, tumor specimens were available only after the development of acquired resistance to gefitinib. Of 6 tumors from 5 patients who showed acquired resistance, 4 tumors had T790M second mutation. No MET amplification was detected in any of these tumors.

**Histology and immunohistochemistry.** Immunohistochemical staining was carried out on formalin-fixed, paraffin-embedded tissue sections of lung adenocarcinoma specimens. Sections of 5-μm thickness were deparaffinized in xylene and rehydrated in decreasing concentrations of ethanol. For detection of MET, sections were retrieved by microwave treatment for 10 min, with immersion in antigen retrieval medium (Immunosaver, Nissin EM Ltd.). After blocking the endogenous peroxidase activity with 3% hydrogen peroxide solution for 10 min, the sections were treated with 3% normal horse serum. The sections were then reacted with primary antibodies (anti-HGF antibody, 5 μg/mL; anti–total MET antibody, 1:100 dilution) at 4°C overnight. The primary antibodies used were rabbit polyclonal anti-HGF antibody (24) and rabbit polyclonal anti-MET antibody (IBL Ltd.). After washing with PBS, the sections were treated with biotin-conjugated antirabbit IgG (1:200 dilution) for 30 min at room temperature and allowed to react for 30 min with avidin-biotin-peroxidase complex (ABC) using a Vectastain ABC kit (Vector Laboratories). The DAB (3,3′-diaminobenzidine tetrahydrochloride) Liquid System (DakoCytomation) was used to detect immunostaining. Omission of primary antibodies served as negative control.

**Evaluation of immunohistochemical results.** Immunoreactivities were evaluated as follows, in accordance with the method of Nakamura and colleagues (27). Immunoreactivities for HGF were evaluated as either high or low, with a cutoff value of 50% of positively stained cancer cells. Immunoreactivities for MET protein were evaluated as follows: --, complete absence of staining or only focal weak staining; 1+, weak to moderate staining in <40% of cancer cells; 2+, weak to moderate staining in at least 40% of cancer cells; 3+, strong staining in at least 10% of cancer cells, among the specimens with weak to moderate staining in at least 40% of cancer cells. Weak to moderate staining was defined as staining similar to or weaker than the staining of normal bronchial epithelium; strong staining was defined as staining clearly more than intense than that of normal bronchial epithelium. Immunoreactivity was evaluated independently by two investigators (S.Y. and W.W.). Cases with discrepancies were jointly reevaluated and a consensus was reached.

**Statistical analysis.** The statistical significance of differences was analyzed by one-way ANOVA. In cases in which the P values for the overall comparisons were <0.05, post hoc pairwise comparisons were done with the Newman-Keuls Multiple comparison test. Statistical analyses were done using GraphPad Prism ver. 4.01 (GraphPad Software, Inc.).

**Results**

HGF induces gefitinib resistance of lung adenocarcinoma cells with EGRF-activating mutations. We first confirmed the presence of activating mutations in EGRF in human lung adenocarcinoma cell lines by direct sequencing, PC-9 and HCC827 had...
Akt and ERK1/2, but not EGFR or ErbB3 (Fig. 2). Even in the presence of gefitinib, HGF restored phosphorylation of MET, Akt, and ERK1/2. Importantly, phosphorylation of EGFR, ErbB3, Akt, and ERK1/2, but not MET. HGF also phosphorylated. Gefitinib inhibited the phosphorylated at various levels. These receptors and downstream Akt and ErbB3, and MET proteins, and these molecules were phosphorylated. PC-9 and HCC827 cells expressed EGFR, ErbB3, and MET proteins, and these molecules were phosphorylated at various levels. These receptors and downstream Akt and ERK1/2 were also phosphorylated. Gefitinib inhibited the phosphorylation of EGFR, ErbB3, Akt, and ERK1/2, but not MET. HGF alone did not affect phosphorylation of EGFR or ErbB3, whereas it stimulated phosphorylation of MET, Akt, and ERK1/2. Importantly, even in the presence of gefitinib, HGF restored phosphorylation of Akt and ERK1/2, but not EGFR or ErbB3 (Fig. 2A).

To investigate the mechanism by which PI3K/Akt phosphorylation is restored by HGF, we immunoprecipitated the p85 regulatory subunit of PI3K and examined the association with MET. In PC-9 and HCC827 cells, ErbB3 was associated with p85, and this association was inhibited by gefitinib. HGF did not affect the association of ErbB3 with p85 irrespective of the presence of gefitinib. MET was constitutively associated with p85, and this association was unaffected by gefitinib and/or HGF. MET was not associated with ErbB3, and neither gefitinib nor HGF induced the association of these two molecules. On the other hand, MET was constitutively associated with EGFR, and this association was disrupted by gefitinib, suggesting that the association between EGFR and MET may be regulated by EGFR phosphorylation status. However, HGF failed to restore the association inhibited by gefitinib (Fig. 2B). These results suggest that HGF-induced resistance is mediated by the MET/PI3K signaling axis but not by the ErbB3/PI3K axis.

**Specific down-regulation of MET, but not ErbB3, reversed gefitinib resistance and phosphorylation of Akt induced by HGF.** We used RNAi technique to confirm this possibility. Down-regulation of ErbB3 expression by an ErbB3-specific siRNA did not affect either HGF-induced resistance to gefitinib or phosphorylation of Akt and ERK1/2 restored by HGF in PC-9 or HCC827 cells. In contrast, down-regulation of MET expression by MET-specific siRNA canceled HGF-induced resistance to gefitinib, as well as phosphorylation of Akt and ERK1/2 restored by HGF (Fig. 3; Supplementary Fig. S5). These results indicate that HGF induces gefitinib resistance by restoring the Akt signaling pathway via MET phosphorylation independently of ErbB3.

**High immunoreactivity for HGF in cancer cells of intrinsic resistant tumors and those with acquired resistance without T790M second mutation or MET amplification.** To assess the clinical relevance of this resistance mechanism, we examined whether HGF as well as MET could be detected in tumors with EGFR-activating mutations obtained from lung adenocarcinoma patients who showed intrinsic resistance (3 cases) or acquired resistance (5 cases) to gefitinib, and a comparison was also made.

Figure 4. High immunoreactivity for HGF in cancer cells of intrinsic resistant tumors and those with acquired resistance without T790M second mutation or MET amplification. Immunohistochemical HGF staining of tumor obtained before gefitinib treatment from patient 4 who showed partial response (A), tumor obtained from patient 4 after acquired resistance by T790M second mutation (B), tumor obtained before gefitinib treatment from patient 1 who showed intrinsic resistance (C), and tumor obtained from patient C after acquired resistance without T790M second mutation or MET amplification (D). Magnification, ×200.
with tumors from responders to gefitinib treatment (8 cases). We analyzed 20 tumors from 16 patients (Table 1). For 3 of 5 patients who developed acquired resistance (i.e., who showed partial response to gefitinib treatment but showed signs of tumor regrowth while still receiving gefitinib), we were able to obtain pairs of tumor specimens before treatment and after the development of acquired resistance to gefitinib. Of 6 acquired resistance tumors from 5 patients, 4 tumors had T790M second mutation. No MET amplification was detected in any of these tumors. HGF and MET immunoreactivity were detected predominantly in cancer cells, as reported by other groups (27). Immunoreactivity for MET protein was detected diffusely in all of 20 tumors (Table 1). Importantly, high levels of immunoreactivity for HGF were detected in cancer cells of 3 of 3 intrinsic resistant tumors and in 1 (patient 7) of 2 tumors with acquired resistance without T790M second mutation or MET amplification, whereas only a low level of HGF immunoreactivity was detected in cancer cells of responders’ tumors (except patient 16) or tumors with acquired resistance with T790M second mutation (Fig. 4; Table 1). These results strongly suggest that HGF produced by cancer cells is involved in resistance to gefitinib in lung adenocarcinomas harboring EGFR-activating mutations.

HGF derived from tumor cells induces gefitinib resistance of lung adenocarcinoma cells with EGFR-activating mutation. To further confirm this, we sought to transfect HGF gene into lung adenocarcinoma cells. PC-9 and HCC827 cells, which are sensitive to gefitinib, secreted undetectable levels of HGF (Fig. 5A). PC-9 cells transfected with human HGF gene (PC-9/HGF), but not vector alone (PC-9/mock), secreted a high level of HGF, and such cells became highly resistant to gefitinib (Fig. 5A and B), but the resistance was abrogated by treatment with anti-HGF neutralizing antibody (Fig. 5C). These results indicate that tumor cell–derived HGF could induce gefitinib resistance of lung adenocarcinoma cells with EGFR-activating mutations.

Discussion
Both intrinsic and acquired resistance to EGFR tyrosine kinase inhibitors are a serious problem in the treatment of lung cancer harboring EGFR-activating mutations. In the present study, we found that HGF induces gefitinib resistance in lung adenocarcinoma cells with EGFR-activating mutations. Despite the limited number of clinical specimens examined, high levels of HGF immunoreactivity were detected in tumors from patients who showed intrinsic resistance (3 of 3 cases) or acquired resistance to gefitinib with no relation to T790M second mutation or MET amplification (1 of 2 cases). These findings indicate that HGF-mediated MET activation is one of the novel mechanisms contributing to intrinsic or acquired gefitinib resistance of lung adenocarcinomas harboring EGFR-activating mutations.

Engelman and colleagues reported that EGFR is linked to PI3K/Akt signaling via ErbB3 in NSCLC cell lines that are sensitive to EGFR tyrosine kinase inhibitors (31) and that MET amplification leads to gefitinib resistance by binding and activation of ErbB3 (12). In the present study, inhibition of ErbB3 with specific antibodies (Fig. 3C) inhibited the growth of PC-9, HCC827, mock-transfected PC-9 (PC-9/mock), and HGF gene–transfected PC-9 (PC-9/HGF) cells. The cells were incubated with or without gefitinib (300 nmol/L) or the presence or absence of HGF (20 ng/mL). Cell growth was measured with Cell Counting Kit-8. Anti-HGF antibody abrogated the resistance of HGF gene–transfected PC-9 cells to gefitinib (Fig. 5C). These results indicate that HGF induces gefitinib resistance without the involvement of ErbB3.
MET can be activated by various mechanisms, including binding by its ligand, HGF (18), amplification of MET gene itself (12), and transactivation by other factors such as EGFR (21). We observed that although human lung adenocarcinoma PC-9 and HCC827 cells did not show MET amplification or produce detectable levels of HGF, MET was phosphorylated at an appreciable level, suggesting transactivation of MET in these cells. Because PC-9 and HCC827 are highly sensitive to gefitinib, MET phosphorylation induced by transactivation may be insufficient to protect cells from apoptosis by gefitinib, and thus HGF-induced activation may be necessary in the presence of gefitinib for survival of lung adenocarcinoma cells harboring EGFRI-activating mutations.

HGF is known to be produced by various stromal component cells as well as tumor cells. Histologic analyses of clinical specimens indicated that HGF is expressed by a significant population of cancer cells, including NSCLC, although HGF is not expressed in a large population of cancer cell lines of many different types in vitro (18). In accordance with these reports, we found that whereas the human lung adenocarcinoma cell lines PC-9 and HCC827 did not secrete detectable levels of HGF in vitro, a high level of HGF was detected predominantly in cancer cells in clinical specimens (32). Therefore, it will be important to clarify the regulatory mechanism of HGF expression in lung cancer cells. Recently, Chen and colleagues (33) reported that cigarette smoking induced overexpression of HGF in lung cancer cells. Nicotine was shown to stimulate HGF production in several NSCLC cell lines. In addition, overexpression of HGF in the tumors was correlated with history of cigarette smoking in lung cancer patients. It is well known that nonsmokers with lung cancer show a more favorable response to gefitinib than smokers (34). Therefore, HGF induced by cigarette smoking may be involved in gefitinib resistance, at least in a specific population of lung cancer patients.

Gene alternation of the target itself or its associated molecules, including secondary mutations (EGFR, KIT, PDGFR, or BCR/ABL) and gene amplification (MET, KIT, or BCR/ABL), were identified as mechanisms of acquired resistance to kinase inhibitors in lung cancer, chronic myeloid leukemia, and gastrointestinal stromal tumors (10–13, 35–38). Our findings provide the new concept that receptor (MET) activation by natural ligand (HGF) without gene mutation or amplification could mediate survival signaling independently of the target or associated molecules (EGFR and ErbB3) against tyrosine kinase inhibitor (gefitinib). Moreover, HGF-MET signaling is a common pathway that has been reported in a number of cancers, including lung, breast, colorectal, prostate, pancreatic, head and neck, gastric, hepatocellular, ovarian, renal, glioma, melanoma, and a number of sarcomas. Therefore, it will be valuable to investigate the involvement of HGF-MET-mediated signaling in acquired resistance to kinase inhibitors in other types of tumors.

The mechanisms responsible for intrinsic resistance to gefitinib in lung cancer harboring EGFRI-activating mutations are poorly understood, although several mechanisms of acquired resistance have been reported (8). To our knowledge, this is the first study to clarify the mechanism of intrinsic resistance to gefitinib in lung cancer harboring EGFRI-activating mutations. Interestingly, all of three intrinsically resistant lung cancers examined showed high levels of HGF immunoreactivity, indicating that HGF plays an important role in intrinsic resistance to gefitinib. In clinical trials, 25% to 30% of lung cancer patients with EGFRI-activating mutations show intrinsic resistance. Thus, our findings suggest the usefulness of combined therapy with EGFRI tyrosine kinase inhibitor and HGF-MET antagonists in these patients. Moreover, because HGF also contributes to acquired resistance to gefitinib, combined therapy may also be applicable for lung cancer showing acquired resistance without T790M second mutation or MET amplification.

There are several possible strategies to inhibit HGF-MET signaling, including anti-HGF neutralizing antibody, HGF antagonist (NK4), and MET tyrosine kinase inhibitors (SU11274, PHA-665752; refs. 18, 39). We found that anti-HGF antibody as well as NK4 (data not shown) efficiently abrogated gefitinib resistance induced by HGF under our in vitro experimental conditions. With regard to EGF-EGFR targeting, both receptor tyrosine kinase inhibitors and monoclonal antibodies have been developed for clinical use. On the other hand, in the case of vascular endothelial growth factor (VEGF)-VEGF receptor targeting, treatment with monoclonal antibody (bevacizumab) has been more successful than with receptor tyrosine kinase inhibitors. Thus, further studies are required to determine which strategy is the most successful for HGF-MET targeting and in vivo experiments are currently ongoing in our laboratory.

In conclusion, we show that HGF-mediated MET activation is a novel mechanism of gefitinib resistance in lung adenocarcinoma with EGFRI-activating mutations. Therefore, inhibition of HGF-MET signaling may be a considerable strategy for more successful treatment with gefitinib.

Disclosure of Potential Conflicts of Interest

T. Mitsudomi: speakers bureau/honoraria and expert testimony, AstraZeneca.

Acknowledgments

Received 5/1/2008; revised 7/21/2008; accepted 9/4/2008.

Grant support: Grants-in-Aid of Cancer Research from the Ministry of Health, Labor, and Welfare of Japan (16-1; S. Yano) and from the Ministry of Education, Science, Sports, and Culture of Japan (17016051; S. Sone).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

We thank Dr I.J. Fidler for helpful discussions and valuable suggestions.

References

8. Mitsudomi T, Yatabe Y. Mutations of the epidermal growth factor receptor gene and related genes as


24. HGF Induces Gefitinib Resistance


Hepatocyte Growth Factor Induces Gefitinib Resistance of Lung Adenocarcinoma with Epidermal Growth Factor Receptor–Activating Mutations

Seiji Yano, Wei Wang, Qi Li, et al.


Updated version
Access the most recent version of this article at:
http://cancerres.aacrjournals.org/content/68/22/9479

Supplementary Material
Access the most recent supplemental material at:
http://cancerres.aacrjournals.org/content/suppl/2008/11/11/68.22.9479.DC1

Cited articles
This article cites 39 articles, 15 of which you can access for free at:
http://cancerres.aacrjournals.org/content/68/22/9479.full#ref-list-1

Citing articles
This article has been cited by 67 HighWire-hosted articles. Access the articles at:
http://cancerres.aacrjournals.org/content/68/22/9479.full#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, use this link http://cancerres.aacrjournals.org/content/68/22/9479.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.